PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats

Acta Pharmacologica Sinica

Volumn 35, Issue 4, 2014, Pages 476-482

  Yousefipour, Zivar ^a   Newaz, Mohammad ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b CHICAGO STATE UNIVERSITY   (United States)

Author keywords

Clofibrate; Hypertension; PPAR ; Proteinuria; Vascular reactivity

Indexed keywords

CLOFIBRATE; NITRATE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; LIGAND; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG MECHANISM; MALE; NONHUMAN; PLETHYSMOGRAPHY; PROTEIN EXPRESSION; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; AGONISTS; ANIMAL; AORTA; BLOOD PRESSURE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; URINE; VASOCONSTRICTION; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CLOFIBRATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; LIGANDS; MALE; NITRIC OXIDE; PPAR ALPHA; PROTEINURIA; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84898763829     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.193     Document Type: Article

References (34)

1. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-Activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011; 2: 236-40
2. Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) α-mediated cardiovascular effects. Mutat Res 2005; 579: 163-71
3. Newaz M, Ranganna K, Truong LD, Oyekan A. Effect of peroxisome proliferator-Activated receptor-Alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypertens 2009; 27: 2223-31
4. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509
5. Diep QN, Benkirane K, Amiri F, Cohn JS, Endermann D, Schiffrin EL. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II infused rats. J Mol Cell Cardiol 2004; 36: 295-304
6. Price ET, Welder GJ, Zineh I. Modulatory effect of fenofibrate on endothelial production of neutrophil chemokines IL-8 and ENA-78. Cardiovasc Drugs Ther 2012; 26: 95-9
7. Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms. Eur J Cell Biol 2011; 90: 657-64
8. Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M, et al. Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int 2011; 79: 871-82
9. Cervantes-Pérez LG, Ibarra-Lara Mde L, Escalante B, Del Valle-Mondragón L, Vargas-Robles H, Pérez-Severiano F, et al. Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension. Eur J Pharmacol 2012; 685: 108-15
10. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-Activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2002; 2: 10-20
11. Newaz MA, Ranganna K, Oyekan AO. Relationship between PPARalpha activation and NO on proximal tubular Na+ transport in the rat. BMC Pharmacol 2004; 4: 1-9
12. Ibarra-Lara L, Cervantes-Pérez LG, Pérez-Severiano F, Del Valle L, Rubio-Ruíz E, Soria-Castro E, et al. PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner. Eur J Pharmacol 2010; 627: 185-93
13. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, et al. Expression of peroxisome proliferator-Activated receptors in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 2000; 61: 67-74
14. Whitworth JA, World Health Organization, International Society of Hypertension Writing 1. Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
15. Iacobazzi V, Convertini P, Infantino V, Scarcia P, Todisco S, Palmieri F. Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem Biophys Res Commun 2009; 388: 643-7
16. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, et al. Peroxisome proliferator-Activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 658-63
17. Mamnoor PK, Hegde P, Datla SR, Damarla RK, Rajagopalan R, Chakrabarti R. Antihypertensive effect of ragaglitazar: A novel PPARalpha and gamma dual activator. Pharmacol Res 2006; 54: 129-35
18. Wilson JL, Duan R, El-Marakby A, Alhashim A, Lee DL. Peroxisome proliferator activated receptor-α agonist slows the progression of hypertension, attenuates plasma interleukin-6 levels and renal inflammatory markers in angiotensin II infused mice. PPAR Res 2012; 2012: 645969
19. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-Activated receptor-α activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension 2005; 46: 366-371
20. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40: 866-71
21. Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, et al. Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodeling in hypertension. J Cell Mol Med 2009; 13: 4444-52
22. Lee L, Wilson JL, Duan R, Hudson T, El-Marakby A. Peroxisome proliferator activated receptor-Alpha activation decreases mean arterial pressure, plasma interleukin-6 and COX-2, while increasing renal CYP4A expression in an acute model of DOCA-salt hypertension. PPAR Res 2011; 2011: 502631
23. Zhou Y, Luo P, Chang HH, Huang H, Yang T, Dong Z, et al. Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats. J Pharmacol Exp Ther 2006; 317: 11-8
24. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-9
25. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25: 194-200
26. Cui X, Liu X, Feng H, Zhao S, Gao H. Grape seed proanthocyanidin extracts enhance endothelial nitric oxide synthase expression through 5'-AMP activated protein kinase/Surtuin 1-rüpple like factor 2 pathway and modulate blood pressure in ouabain induced hypertensive rats. Biol Pharm Bull 2012; 35: 2192-7
27. Li H, Witte K, August M, Brausch I, Gödtel-Armbrost J, Habermeier A, et al. Reversal endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006; 47: 2536-44
28. Bulhak AA, Sjöquist PO, Xu CB, Edvinsson L, Pernow J. Protection against myocardial ischaemia/reperfusion injury by PPAR-Alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 2006; 101: 244-52
29. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-Activated receptor-α and-γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23: 45-51
30. Banks T, Oyekan A. Peroxisome proliferator-Activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens 2008; 26: 468-77
31. Jonkers IJ, de Man FH, van der Laarse A, Frölich M, Gevers Leuven JA, Kamper AM, et al. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 2001; 19: 749-55
32. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006; 71: 247-58
33. Walusimbi-Kisitu M, Harrison EH. Fluorometric assay for rat liver peroxisomal fatty acyl-coenzyme A oxidase activity. J Lipid Res 1983; 24: 1077-84
34. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension 2005; 45: 730-5.